Tumor Response in the Targeted Population Through the End of Treatment Baseline and then every 8 weeks through end of treatment [clinicaltrials_resource:ec07acb20e0852e8ee1155e3ac7d655f]
Disease progression and tumor response (number of participants achieving a complete response [CR] or partial response [PR]), using standardized criteria (Response evaluation criteria in solid tumors). CR, disappearance of all target lesions; PR, 30% decrease in the sum of the longest diameter of target lesions; progressive disease, 20% increase in the sum of the longest diameter of target lesions; stable disease, small changes that do not meet above criteria. Disease assessment was done at baseline and then every 8 weeks after starting treatment, until the participant discontinued treatment.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Tumor Response in the Targeted Population Through the End of Treatment Baseline and then every 8 weeks through end of treatment [clinicaltrials_resource:ec07acb20e0852e8ee1155e3ac7d655f]
Disease progression and tumor response (number of participants achieving a complete response [CR] or partial response [PR]), using standardized criteria (Response evaluation criteria in solid tumors). CR, disappearance of all target lesions; PR, 30% decrease in the sum of the longest diameter of target lesions; progressive disease, 20% increase in the sum of the longest diameter of target lesions; stable disease, small changes that do not meet above criteria. Disease assessment was done at baseline and then every 8 weeks after starting treatment, until the participant discontinued treatment.
Bio2RDF identifier
ec07acb20e0852e8ee1155e3ac7d655f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:ec07acb20e0852e8ee1155e3ac7d655f
measure [clinicaltrials_vocabulary:measure]
Tumor Response in the Targeted Population Through the End of Treatment
time frame [clinicaltrials_vocabulary:time-frame]
Baseline and then every 8 weeks through end of treatment
description
Disease progression and tumor ...... cipant discontinued treatment.
identifier
clinicaltrials_resource:ec07acb20e0852e8ee1155e3ac7d655f
title
Tumor Response in the Targeted ...... weeks through end of treatment
@en
type
label
Tumor Response in the Targeted ...... 7acb20e0852e8ee1155e3ac7d655f]
@en